The FDA released 14 new drug rejection letters after a three-month pause in a transparency policy for publishing those documents. The publication follows the agency’s confirmation to Fierce that the release process was halted in April, according to the report. The move matters for sponsors tracking regulatory feedback and for analysts assessing how clinical or manufacturing deficiencies are being communicated in real time across review cycles.